Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants
NCT07371455 is registered in ClinicalTrials.gov with Longwood Pharmaceuticals (Hangzhou) Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants
- Lead sponsor
- Longwood Pharmaceuticals (Hangzhou) Co., Ltd.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- March 13, 2026
- Completion date
- September 30, 2026
- Enrollment
- 76 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.